Trial · NCT07403604
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hepatic de novo lipogenesis (absolute values) | Study Days 8 and 16 | Percent incorporation of newly synthesized fatty acids into serum or very low-density lipoprotein (VLDL) triglyceride (TG) (units: %) |
| Primary | Hepatic de novo lipogenesis (relative/change) | Study Days 8 and 16 | Percent incorporation of newly synthesized fatty acids into serum or VLDL TG (units: fold difference and/or ∆%) |
| Secondary | Fasting plasma/serum insulin (absolute values) | Study Days 8 and 16 | Measurement of fasting endogenous insulin levels during treatment with diazoxide 2 mpk vs. placebo (units: micro-international units \[µIU\] per mL). |
| Secondary | Fasting plasma/serum insulin (relative/change) | Study Days 8 and 16 | Measurement of fasting endogenous insulin levels during treatment with diazoxide 2 mpk vs. placebo (units: fold difference and/or change in µIU/mL). |
| Secondary | Fasting plasma glucose | Study Days 8 and 16 | Measurement of fasting plasma glucose levels during treatment with diazoxide 2 mpk vs. placebo (units: mg/dL). |
| Secondary | Fasting serum or plasma triglycerides | Study Days 8 and 16 | Measurement of fasting plasma or serum triglyceride levels during treatment with diazoxide 2 mpk vs. placebo (units: mg/dL). |
| Secondary | Fasting plasma free fatty acids | Study Days 8 and 16 | Measurement of fasting plasma free fatty acid levels during treatment with diazoxide 2 mpk vs. placebo (units: mmol/L). |
| Secondary | Steady state plasma glucose (SSPG) during IST | At time points of 150, 160, 170, and 180 minutes during each 3-hour IST protocol | Measurement of plasma glucose at 10-minute intervals during 30-minute steady-state period at the end of each IST (units: mg/dL) |
| Other | Skin de novo lipogenesis | 3 hours | Percent incorporation of newly synthesized fatty acids into sebum from healthy skin and, if present, skin from inflammatory skin lesions (units: %) |
| Other | Deuterium tracer enrichment in body water (measured in blood) | Study Days 8 and 16 | Enrichment of total body water with deuterated water (2H2O/D2O) (units: %) |
| Other | Deuterium tracer enrichment in body water (measured in saliva) | Study Days 8 and 16 | Enrichment of total body water with deuterated water (2H2O/D2O) (units: %) |
| Other | Deuterium tracer enrichment in sebum | 3 hours | Enrichment of sebum with deuterated water (2H2O/D2O) (units: %) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07403604/registered